CABENUVA offers virologically suppressed adolescents 12 years of age or older living with HIV-1 an injectable treatment option with as few as six dosing days per year
regardless of whether they continued to receive monthly injections every four weeks or were randomized to the every-eight-weeks arm. Among the 191 participants who switched from monthly to every-other-month administration
the first and only once-monthly, long-acting regimen for the treatment of HIV-1 infection in adults. CABENUVA™ is indicated as a complete regimen for the treatment of